Seminars in Thoracic and Cardiovascular Surgery
Volume 21, Issue 2 , Pages 149-153 , Summer 2009

Surgical Options in Malignant Pleural Mesothelioma: Extrapleural Pneumonectomy or Pleurectomy/Decortication

  • Raja M. Flores, MD

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Raja M. Flores, MD, Thoracic Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021

References 

  1. Flores RM, Krug LM, Rosenzweig KE, et al. Induction chemotherapy, extrapleural pneumonectomy, and postoperative high-dose radiotherapy for locally advanced malignant pleural mesothelioma: A phase II trial. J Thorac Oncol. 2006;1:289–295
  2. Weder W, Kestenholz P, Taverna C, et al. Neoadjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. J Clin Oncol. 2004;22:3451–3457
  3. Sugarbaker DJ, Flores RM, Jaklitsch MT, et al. Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: Results of 183 patients. J Thorac Cardiovasc Surg. 1999;117:54–65
  4. Martin-Ucar AE, Nakas A, Edwards JG, et al. Case control study between extrapleural pneumonectomy and radical pleurectomy/decortication for pathological N2 malignant pleural mesothelioma. EJCTS. 2007;31:765–770
  5. Richards WG, Zellos L, Bueno R, et al. Phase i to ii study of pleurectomy/decortication and intraoperative intracavitary hyperthermic cisplatin lavage for mesothelioma. J Clin Oncol. 2006;24:1561–1567
  6. Rusch VW, Rosenzweig K, Venkatraman E, et al. A phase ii trial of surgical resection and adjuvant high dose hemithoracic radiation for malignant pleural mesothelioma. J Thorac Cardiovasc Surg. 2001;122:788–795
  7. Lee TT, Everett DL, Shu H-KG, et al. Radical pleurectomy/decortication and intraoperative radiotherapy followed by conformal radiation with or without chemotherapy for malignant pleural mesothelioma. J Thorac Cardiovasc Surg. 2002;124:1183–1189
  8. Hilaris BS, Dattatreyudu N, Kwong E, et al. Pleurectomy and intraoperative brachytherapy and postoperative radiation in the treatment of malignant pleural mesothelioma. Int J Radiat Oncol Biol Phys. 1984;10:325–331
  9. McCormack PM, Nagasaki F, Hilaris BS, et al. Surgical treatment of pleural mesothelioma. J Thorac Cardiovasc Surg. 1982;84:834–842
  10. Pass HI, Temeck BK, Kranda K, et al. Phase iii randomized trial of surgery with or without intraoperative photodynamic therapy and postoperative immunochemotherapy for malignant pleural mesothelioma. Ann Surg Oncol. 1997;4:628–633
  11. Lu C, Perez-Soler R, Piperdi B, et al. Phase ii study of a liposome-entrapped cisplatin analog (L-NDDP) administered intrapleurally and pathologic response rates in patients with malignant pleural mesothelioma. J Clin Oncol. 2005;23:3495–3501
  12. Allen KB, Faber LP, Warren WH. Malignant pleural mesothelioma (Extrapleural pneumonectomy and pleurectomy). Chest Surg Clin North Am. 1994;4:113–126
  13. Stewart DJ, Martin-Ucar A, Pilling JE, et al. The effect of extent of local resection on patterns of disease progression in malignant pleural mesothelioma. Ann Thorac Surg. 2004;78:245–252
  14. Flores RM, Pass HI, Seshan VE, et al. Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: Results in 663 patients. J Thorac Cardiovasc Surg. 2008;135:620–626
  15. Sugarbaker DJ. Macroscopic complete resection; the goal of primary surgery in multimodality therapy for pleural mesothelioma. J Thorac Oncol. 2006;1:175–176
  16. In:  Greene FL,  Page DL,  Fleming ID, et al. editor. AJCC Cancer Staging Handbook. (ed 6). New York, NY: Springer-Verlag; 2002;
  17. Flores RM, Zakowski M, Venkatraman E, et al. Prognostic factors in the treatment of malignant pleural mesothelioma (MPM) at a large Tertiary Referral Center. J Thorac Oncol. 2007;2:957–965
  18. Pass HI, Temeck BK, Kranda K, et al: Preoperative tumor volume is associated with outcome in malignant pleural mesothelioma. J Thorac Cardiovasc Surg 115:310-317v
  19. Flores RM, Routledge T, Seshan VE, et al. The impact of lymph node station on survival in 348 surgically resected malignant pleural mesothelioma (MPM) patients: Implications for revision of the AJCC staging system. J Thorac Cardiovasc Surg. 2008;136:605–610
  20. Flores RM, Akhurst T, Gonen M, et al. Positron emission tomography (PET) predicts survival in malignant pleural mesothelioma (MPM). J Thorac Cardiovasc Surg. 2006;132:763–768
  21. Flores RM, Akhurst T, Gonen M, et al. Positron emission tomography defines metastatic disease but not locoregional disease in patients with malignant pleural mesothelioma. J Thorac Cardiovasc Surg. 2003;126:11–16
  22. Pass HI, Kranda K, Temeck B, et al. Surgically debulked malignant pleural mesothelioma: Results and prognostic factors. Ann Surg Oncol. 1997;4:215–222
  23. Byrne MJ, Davidson JA, Musk AW, et al. Cisplatin and gemcitabine treatment for malignant mesothelioma: A phase II study. J Clin Oncol. 1999;17:25–30
  24. Van Meerbeeck JP, Gaafar R, Manegold C, et al. Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: An intergroup study of the European Organization for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol. 2005;23:6881–6889
  25. Vogelzang NJ, Rusthoven J, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003;21:2636–2644

PII: S1043-0679(09)00072-0

doi: 10.1053/j.semtcvs.2009.06.008

Seminars in Thoracic and Cardiovascular Surgery
Volume 21, Issue 2 , Pages 149-153 , Summer 2009

Article Tools

* Image Usage & Resolution